See more : DelphX Capital Markets Inc. (DELX.V) Income Statement Analysis – Financial Results
Complete financial analysis of EV Biologics, Inc. (YECO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of EV Biologics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Waystream Holding AB (publ) (WAYS.ST) Income Statement Analysis – Financial Results
- Courtside Group, Inc. Common Stock (PODC) Income Statement Analysis – Financial Results
- ZhongWang Fabric Co., Ltd. (605003.SS) Income Statement Analysis – Financial Results
- Ganga Papers India Limited (GANGAPA.BO) Income Statement Analysis – Financial Results
- International Gold Resources Inc. (IGRU) Income Statement Analysis – Financial Results
EV Biologics, Inc. (YECO)
About EV Biologics, Inc.
EV Biologics, Inc., a biotechnology company, engages in the commercial development of extracellular vesicles (EVs) as biological modalities for diagnostics and therapeutics. It is involved in developing vaccines, therapeutics, and cures based on its proprietary multifunctional EV platform. The company also focuses on developing human mesenchymal and other stem cell, and cell-derived products to market in the cosmetic and biopharmaceutical spaces. The company was formerly known as Yulong Eco-Materials Limited and changed its name to EV Biologics, Inc. in August 2020. EV Biologics, Inc. was incorporated in 2011 and is headquartered in Cheyenne, Wyoming.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 48.90K | 0.00 | 118.90K | 0.00 | 0.00 | 9.47M | 42.64M | 46.23M | 44.46M | 42.48M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.94M | 26.17M | 29.36M | 27.50M | 26.78M |
| Gross Profit | 48.90K | 0.00 | 118.90K | 0.00 | 0.00 | 1.54M | 16.48M | 16.87M | 16.95M | 15.70M |
| Gross Profit Ratio | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 16.24% | 38.64% | 36.49% | 38.13% | 36.95% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 759.22K | 12.84M | 3.37M | 806.04K | 711.95K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 624.68K | 451.93K | 634.39K | 930.47K | 869.30K |
| SG&A | 531.96K | 590.04K | 143.16K | 98.96K | 98.40K | 1.38M | 13.29M | 4.01M | 1.74M | 1.58M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -102.46K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 531.96K | 590.04K | 143.16K | 98.96K | 98.40K | 1.38M | 13.29M | 4.01M | 1.74M | 1.58M |
| Cost & Expenses | 531.96K | 590.04K | 143.16K | 98.96K | 98.40K | 9.32M | 39.46M | 33.37M | 29.24M | 28.36M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 111.33K | 70.07K | 18.19K | 3.61K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 576.38K | 1.04M | 1.30M | 1.18M | 1.15M |
| Depreciation & Amortization | 167.90K | 228.49K | 236.56K | 206.30K | 171.86K | 687.00K | 2.22M | 1.77M | 1.39M | 1.05M |
| EBITDA | -1.27M | -21.06M | -387.70K | -98.96K | -98.40K | -6.64M | -5.82M | -46.57M | 14.63M | 16.54M |
| EBITDA Ratio | -2,591.27% | 0.00% | -20.40% | 0.00% | 0.00% | 7.80% | 12.91% | 31.64% | 37.35% | 35.70% |
| Operating Income | -483.06K | -590.04K | -24.26K | -98.96K | -98.40K | 52.40K | 3.29M | 12.86M | 15.22M | 14.12M |
| Operating Income Ratio | -987.86% | 0.00% | -20.40% | 0.00% | 0.00% | 0.55% | 7.71% | 27.81% | 34.23% | 33.23% |
| Total Other Income/Expenses | -784.07K | -20.47M | -363.44K | -1.00 | -3.00 | -678.84K | -1.32M | -332.56K | -1.28M | -1.27M |
| Income Before Tax | -1.27M | -21.06M | -387.70K | -98.96K | -98.40K | -523.99K | -49.83M | 11.58M | 13.95M | 12.96M |
| Income Before Tax Ratio | -2,591.28% | 0.00% | -326.07% | 0.00% | 0.00% | -5.53% | -116.86% | 25.04% | 31.38% | 30.50% |
| Income Tax Expense | -167.90K | -228.49K | -236.56K | -206.30K | -171.86K | 27.59K | 3.36M | 2.90M | 3.26M | 2.91M |
| Net Income | -1.27M | -21.06M | -387.70K | -98.96K | -98.40K | -551.58K | -53.19M | 8.68M | 10.69M | 10.05M |
| Net Income Ratio | -2,591.28% | 0.00% | -326.07% | 0.00% | 0.00% | -5.82% | -124.73% | 18.77% | 24.05% | 23.66% |
| EPS | -0.12 | -2.91 | -0.05 | -0.01 | -0.02 | 0.00 | -22.30 | 5.40 | 6.94 | 5.24 |
| EPS Diluted | -0.12 | -2.91 | -0.05 | -0.01 | -0.02 | 0.00 | -22.30 | 5.40 | 6.94 | 5.24 |
| Weighted Avg Shares Out | 10.23M | 7.23M | 7.23M | 7.23M | 6.43M | 2.41M | 2.39M | 1.60M | 1.53M | 1.92M |
| Weighted Avg Shares Out (Dil) | 10.23M | 7.23M | 7.23M | 7.23M | 6.43M | 2.41M | 2.39M | 1.60M | 1.53M | 1.92M |
EV Biologics Unveils NFT Dividend Warrant
EV Biologics Signs LOI with Lonza Cell & Gene Therapy
EV Biologics Confirms Funding to Commence Cell Line Generation & Advance Exosome Research
Source: https://incomestatements.info
Category: Stock Reports